F2695

DRUG2 trials

Sponsors

Pierre Fabre Medicament

Conditions

Ischemic StrokeSubject

Phase 1

Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging

CompletedNCT02266966

Pierre Fabre MedicamentSubject

Start: 2014-04-30End: 2014-09-30Updated: 2016-10-13

Phase 3

Effect of F2695 on Functional Recovery After Ischemic Stroke

CompletedNCT01639014

Pierre Fabre MedicamentIschemic Stroke

Start: 2012-07-31End: 2015-02-28Updated: 2015-04-01